Background: Drug-induced QT prolongation is associated with higher risk of cardiac arrhythmias and cardiovascular mortality. We investigated the effects of atypical antipsychotic drugs on QT interval in children and adults with mental disorders.
Introduction
Observational studies provide consistent evidence that prolonged QT interval is associated with higher risk of all-cause and cardiovascular mortality (1) . Drug-induced prolongation of QT contributes to higher mortality (2, 3) .
The risk of drug-induced prolongation of QT is much higher in older adults and people with multiple chronic conditions (4) . Psychotropic drugs including atypical antipsychotic agents are commonly prescribed for licensed and off-label indications and may contribute to the higher risk of drug-induced QT prolongation (5, 6) . This rapid review focuses on the effects of atypical antipsychotic drugs on QT interval in children and adults with mental disorders.
Methods
We used a standard recommended methodology in conducting systematic literature reviews and meta-analyses from the Cochrane Collaboration and the Agency for Healthcare Research and Quality (7, 8) . We developed a priori protocol for a systematic literature review to answer the clinical question about the safety of atypical antipsychotic drugs on QT interval in children and adults with mental disorders.
We defined the target population as people with mental disorders treated with atypical antipsychotic drugs. Eligible interventions included atypical antipsychotics when compared with placebo or other antipsychotic medications. Eligible outcomes included change in QT Interval, clinically important prolongation of QT corrected to RR interval ≥450 msec in men ≥480 msec in women, and QTc ≥500 msec associated with increased risk of life-threatening torsades de pointes ventricular tachycardia (9) .
We conducted a comprehensive search in PubMed, EMBASE, the Cochrane Library, www.clinicaltrials.gov and PharmaPendium (www.pharmapendium.com) up to October 2017 to find systematic reviews, published and unpublished RCTs, and nationally represented controlled observational studies that reported adjusted effect estimates (7, 8) . All of the authors determined the studies' eligibility. All citations found during the searches are stored in a reference database.
The data was extracted from the Clinical Trials Transformation Initiative (CTTI) (https://www.ctticlinicaltrials.org/aact-database), checked for quality, and stored in the HPCC platform (High-Performance Computing Cluster, https://hpccsystems.com/).
We performed direct frequentist meta-analyses of aggregate data when definitions of the active and control intervention and patient outcomes were deemed similar for pooling (10) . We used random effects models to address inevitable differences in patient characteristics across primary RCTs. For each abstracted hypothesis, we calculated absolute risk difference and relative risk with 95% CI. We calculated number needed to treat and number of attributable events per 1,000 treated with 95% CI based on statistically significant differences in absolute risks of the outcomes. We examined consistency in results across studies with chi-square tests and I 2 statistics and concluded statistically significant heterogeneity if I 2 was >50% (7).
Statistically significant heterogeneity did not preclude statistical pooling (10) . However, we planned exploring heterogeneity with a priori defined patient characteristics, drug doses, and study quality if this information was available in the studies (10) . We used consensus method guidelines for systematic review and meta-analyses that do not recommend conducting post hoc analyses of statistical power (11) (12) (13) (14) . Instead, we downgraded our confidence in true treatment effects based on calculated optimal information size as the number of patients required for an adequately powered individual trial (15) . Since power is more closely related to number of events than to sample size, we concluded imprecision in treatment effects if fewer than 250 patients experienced the event (15) .
We used Statistics/Data Analysis, STATA software (StataCorp LP, College Station, Texas). Statistical significance was evaluated at a 95% confidence level.
We evaluated the quality of systematic reviews using the Assessment of Multiple Systematic Reviews (AMSTAR) (16) . For primary RCTs, we used the Cochrane risk of bias tool on a 3-point scale: high bias, low bias, and unclear (17, 18) . A low risk of bias was assumed when RCTs met all the riskof-bias criteria, a medium risk of bias if at least 1 of the riskof-bias criteria was not met, and a high risk of bias if two or more risk-of-bias criteria were not met. An unknown risk of bias was assigned for the studies with poorly reported risk-of-bias criteria. We assigned high risk of bias to all observational studies.
The authors assigned the quality of evidence ratings as high, moderate, low, or very low, according to risk of bias in the body of evidence, directness of comparisons, precision and consistency in treatment effects, and the evidence of reporting bias, using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (19) .
A high quality of evidence was assigned to well-designed RCTs with consistent findings. The quality of evidence was downgraded to moderate if at least 1 of 4 quality of evidence criteria was not met; for example, moderate quality of evidence was assigned if there was a high risk of bias in the body of evidence or if the results were not consistent or precise. The quality of evidence was downgraded to low if two or more criteria were not met. We concluded a high risk of bias in the body of evidence if at least one RCT had high risk of bias. We downgraded the quality of evidence © Annals of Translational Medicine. All rights reserved.
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A low quality of evidence was assigned to nonrandomized studies, but the rating was upgraded if there was a strong or dose-response association (20) . Evidence was defined as insufficient when no studies provided valid information about treatment effects. This approach was applied regardless of whether the results were statistically significant.
Results
Our comprehensive search in PubMed, EMBASE, the Cochrane Library, and clinicaltrials.gov up to May 2017 identified clinical studies that examined aripiprazole, quetiapine, risperidone, olanzapine, ziprasidone or brexpiprazole.
Risperidone was examined in three systematic reviews and meta-analyses, one individual patient data network meta-analysis of 64 RCTs, published and unpublished data from six RCTs and six non-randomized studies (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) .
Evidence suggests that risperidone is associated with QT prolongation in children and adolescents with mental disorders (Table 1) .
A single industry-sponsored individual patient metaanalysis of 64 RCTs suggests that risperidone results in QT prolongation when compared with placebo in adults with mental disorders ( Table 1 ). The evidence from the FDA Adverse Event Reporting System database suggests that risperidone is associated with greater odds of torsades de pointes ventricular tachycardia in adults with indication for antipsychotics ( Table 1) . Industry-sponsored postmarketing analysis suggests that all cases of ventricular tachycardia have been associated with overdose of risperidone (41) .
The direct evidence of comparative safety between risperidone and other antipsychotics is sparse. Risperidone is associated with QT abnormalities when compared with aripiprazole in pediatric patients with mental disorders and concomitant use of stimulants ( Table 2 ). Some evidence suggests that there are no differences in QT abnormalities or rates of torsades de pointes between risperidone and atypical antipsychotics or haloperidol in adults with mental disorders ( Table 2) . A single RCT suggests that risperidone decreases QT interval when compared with ziprasidone ( Table 2) .
Post-marketing surveillance suggests 43 cases of prolonged QT intervals and 71 cases of torsades de pointes tachycardia in people treated with risperidone among other medications for various mental disorders (Table S1) . Ziprasidone was examined in four systematic reviews and meta-analyses, one industry sponsored individual patient data network meta-analysis and published and unpublished data from 11 RCTs and three non-randomized trials (30, 35, 37, 38, (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) .
Evidence suggests that ziprasidone increases QT interval and the rates of QT prolongation by >30 msec when compared with placebo ( Table 3) or haloperidol ( Table 4 ) in people with mental disorders. Ziprasidone also prolongs QT interval when compared with olanzapine and risperidone ( Table 5 ). There are no differences in the length of QT interval after treatment with ziprasidone versus aripiprazole ( Table 5) . Chlorpromazine increases the duration of QT interval when compared with ziprasidone ( Table 5) .
Available studies did not report the rates of torsade de pointes ventricular tachycardia in adults treated with ziprasidone. Post-marketing observational study suggested no differences in mortality after 1-year treatments with ziprasidone versus olanzapine in 18,154 adults with schizophrenia (Table S2) . Post-marketing surveillance identified 202 cases of prolonged QT interval and 83 cases of torsade de pointes in patients treated with ziprasidone among other drugs ( Table S1 ).
The evidence is applicable mostly to adults. Pediatric studies reported no events of QT prolongation after higher (160 mg/day) or lower (20 mg/d titrated to between 80 mg/day) doses on ziprasidone (37, 42) .
Olanzapine was examined in four systematic reviews and meta-analyses and one individual patient data network meta-analysis. (35, 37, 38, 57, 58) . We also identified published and unpublished data from 20 RCTs and 1 non-randomized trial (30, 43, .
Available low-quality evidence suggests that olanzapine has no effect on QT interval when compared with placebo in children and adolescents with mental disorders (Table 6 ). We also found that that oral olanzapine has no effect on QT interval while intramuscular olanzapine decreases QT interval when compared with placebo in adults with mental disorders ( Table 6) .
A single small RCT suggests that there are no differences in QT interval between olanzapine and haloperidol in children and adolescents with autistic disorder ( Table 7 ). Moderate quality evidence suggests that there are no differences in QT interval between olanzapine and , we concluded that there is no difference in outcomes between active and control interventions based on P>0.05 and inability to reject null hypotheses but without posthoc analysis of the statistical power to detect true differences. 95% confidence interval in ()/[]; GRADE, Grading of Recommendations Assessment, Development and Evaluation; OR, odds ratio; NNT, number needed to treat to achieve an outcome in one patient; NNT is calculated as 1/absolute risk difference; attributable events per 1,000 treated as the number of excessive or avoided events per 1,000 treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as absolute rate difference multiplied by 1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0-0.5 standard deviations), moderate (SMD, 0.5-0.8 standard deviations), and large (SMD >0.8 standard deviations); QTcLD, interval corrected for heart rate using the population specified linear derived method; NR, not reported. † , we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without posthoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and Evaluation; OR, odds ratio; NNT, number needed to treat to achieve an outcome in one patient; NNT is calculated as 1/absolute risk difference; attributable events per 1,000 treated as the number of excessive or avoided events per 1000 treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as absolute rate difference multiplied by 1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0-0.5 standard deviations), moderate (SMD, 0.5-0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; NR, not reported. concluded that there is no difference in outcomes between active and control interventions based on P value>0.05 and inability to reject null hypotheses but without post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0-0.5 standard deviations), moderate (SMD, 0.5-0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; NR, not reported. , we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without post-hoc analysis of the statistical power to detect true differences. *, no statistically significant differences in absolute risk. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0-0.5 standard deviations), moderate (SMD, 0.5-0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; NR, not reported. No difference † , we concluded that there is no difference in outcomes between active and control interventions based on P>0.05 and inability to reject null hypotheses but without posthoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and Evaluation; NNT, number needed to treat to achieve an outcome in one patient; NNT is calculated as 1/absolute risk difference; attributable events per 1,000 treated as the number of excessive or avoided events per 1,000 treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as absolute rate difference multiplied by 1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0-0.5 standard deviations), moderate (SMD, 0. (Table 7) . Intramuscular olanzapine decreases QT interval when compared with haloperidol in agitated adults ( Table 7) .
Post-marketing surveillance suggests 84 cases of prolonged QT intervals and 53 cases of torsades de pointes tachycardia in people treated with olanzapine among other medications for various mental disorders (Table S1) .
Quetiapine was examined in two systematic reviews and meta-analyses (38, 80) . We also identified published and unpublished data from 7 RCTs and 4 non-randomized studies (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (81) (82) (83) (84) (85) (86) .
When compared with placebo or no active treatment, evidence suggests that quetiapine is not associated with the risk of QT prolongation in children and adolescents ( Table 8 ). In contrast, quetiapine is associated with higher odds of torsade's de pointes or QT interval abnormalities in adult patients with mental disorders (Table 8) .
When compared with other antipsychotics, sparse evidence suggests that there are no differences in QT interval between quetiapine and haloperidol or risperidone ( Table 9) . Sparse data from a single RCT suggests that quetiapine decreases QT interval when compared with ziprasidone in adults with mental disorders ( Table 9 ). Observational analysis of Medicaid database demonstrates that quetiapine is associated with the lower risk of torsade's de pointes or sudden cardiac death when compared with olanzapine ( Table 9) .
Post-marketing surveillance suggests 56 cases of prolonged QT intervals and 90 cases of torsade's de pointes tachycardia in people treated with olanzapine among other medications for various mental disorders (Table S1) .
Aripiprazole was examined in four systematic reviews and meta-analyses and published and unpublished data from 12 RCTs and three non-randomized trials (35) (36) (37) (60) (61) (62) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) .
Evidence suggests that there are no differences in QT interval changes or rates of prolonged QT interval between aripiprazole and placebo, risperidone or haloperidol in adults with mental disorders (Table 10 ). Higher dose of aripiprazole does not increase QT interval when compared with the lower dose ( Table 10) . Available studies did not report the rates of torsade de pointes ventricular tachycardia in adults treated with aripiprazole. Post-marketing surveillance identified 15 cases of prolonged QT interval and 21 cases of torsade de pointes in patients treated with aripiprazole among other drugs (Table S1 ).
Sparse evidence suggests that aripiprazole is associated with reduction in QT interval in pediatric patients with mental disorders (Table 11 ). Sparse evidence suggests that there are no differences in the rates of prolonged QT interval between aripiprazole, placebo, risperidone or pimozide in children and adolescents with mental disorders ( Table 11 ).
The evidence regarding the role of chronic inflammation or genetic polymorphism on QT interval in patients taking aripiprazole is insufficient (98-100) .
Aripiprazole may present a safer choice in patients who need antipsychotic drugs and have no cardiac disorders associated with higher risk of cardiac death (101) .
Brexpiprazole was examined in one systematic review and unpublished data from four RCTs (102) (103) (104) (105) .
Evidence suggests that there are no differences in the rates of the prolonged (>500 msec or increase by >60 msec) QT interval between brexpiprazole and placebo in adults with mental disorders (Table 12) . Sparse evidence from a single unpublished RCT suggests that the lower (4 mg) but not higher (12 mg) dose of brexpiprazole prolongs QT interval when compared with placebo ( Table 12) . The evidence regarding effects of brexpiprazole on QT interval in children is insufficient. The evidence regarding comparative safety between brexpiprazole and other antipsychotics on QT interval or the risk of ventricular tachycardia is insufficient.
Post-marketing surveillance does not detect cases of prolonged QT intervals or torsades de pointes tachycardia in people treated with brexpiprazole among other medications for various mental disorders (Table S1 ).
Discussion
Our review of clinical trials, observational studies and postmarketing surveillance found mostly low quality of evidence concerning higher risk of antipsychotic drugs induced QT prolongation. In people with mental disorders referred for treatment with atypical antipsychotic drugs, in order to avoid QT prolongation and reduce the risk of ventricular tachycardia clinicians may recommend aripiprazole, brexpiprazole or olanzapine in licensed doses.
Our findings are in concordance with previously published observational studies that reported a positive association between antipsychotic drugs and the increased risk of cardiac arrest (106) (107) (108) .
We downgraded the quality of evidence due to the high risk of bias and small number of events in the RCTs. The majority of clinical studies did not have statistical , we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and Evaluation; OR, odds ratio; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0−0.5 standard deviations), moderate (SMD, 0.5−0.8 standard deviations), and large (SMD >0.8 standard deviations); QTcLD, interval corrected for heart rate using the population specified linear derived method; NR, not reported. No difference † , we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and Evaluation; HR, hazard ratio; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0-0.5 standard deviations), moderate (SMD, 0.5-0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; QTcF , Fridericia's corrected QT interval; NR, not reported. , we concluded that there is no difference in outcomes between active and control interventions based on P value>0.05 and inability to reject null hypotheses but without post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0-0.5 standard deviations), moderate (SMD, 0.5-0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; NR, not reported. , we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and Evaluation; NNT, number needed to treat to achieve an outcome in one patient; NNT is calculated as 1/absolute risk difference; attributable events per 1,000 treated as the number of excessive or avoided events per 1,000 treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as absolute rate difference multiplied by 1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0-0.5 standard deviations), moderate (SMD, 0.5-0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; NR, not reported.
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2018;6(8):147 atm.amegroups.com power to detect higher risk of ventricular tachycardia. We further downgraded the quality of evidence due to reporting bias because very small proportion of primary studies that examined benefits of atypical antipsychotics also examined drug-induced QT prolongation. Retrospective post-marketing case reports collection is biased because the reporting depends on clinician opinion regarding the association between ventricular tachycardia and administration of antipsychotic drugs (109) .
Available industry guidelines recommend intensive ECG monitoring of QT intervals in clinical trials of non-antiarrhythmic drugs with suspected proarrhythmic potential but do not require proactive postmarketing monitoring in real-life settings (110) . Some clinical guidelines recommend careful consideration of individual benefits and harms including drug-induced QT prolongation in people with mental disorders and indication for antipsychotic drugs (111-113). Only two British guidelines and one US guideline meet 2013 Institute of Medicine criteria for trustworthy guidelines (111-113). Drug labels recommend against administration of quetiapine or ziprasidone in combination with other drugs that are known to prolong QT interval and in people with bradycardia, hypokalemia or hypomagnesemia, congenital prolongation of the QT interval (114, 115) . Despite these recommendations, prevalence of polypharmacy with multiple pro-arrhythmic drugs is high (2, 4, 101) .
Our review has implications for clinical practice. Clinicians should evaluate baseline risk for cardiac arrhythmias before offering atypical antipsychotic drugs (116) . Routine ECG monitoring for the prolongation of QT interval should be recommended for all patients under the treatment with atypical antipsychotic drugs (117) . Multidisciplinary coordinated care should be practiced to avoid polypharmacy with multiple pro-arrhythmic drugs (116, 118) . Patients should be proactively examined for clinical symptoms indicating the occurrence of cardiac arrhythmias, e.g., dizziness, palpitations, or syncope (119) . Our review has policy implications. Prescribing quality in compliance with licensed drug use should be routinely evaluated with electronic decision support systems. (114, 115, 120) . Proactive technologically advanced pharmacovigilance applications should be implemented to decrease the risk of drug-induced QT prolongation and cardiac arrhythmias (109, (121) (122) (123) (124) .
Our review has research implications. Future proactive post-marketing surveillance should examine long-term comparative safety of atypical antipsychotic drugs in patients with different age, primary diagnosis and multiple comorbidities and concomitant drugs. Novel technology applications and adequate statistical methods should be used for routine analysis of antipsychotic-induced QT prolongation and cardiac arrhythmias.
